Differences in Survival Improvement Between Known and Unknown Primary Merkel Cell Carcinoma in the Era of Immune Checkpoint Inhibitors
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://data.mendeley.com/datasets/brxp657w22
下载链接
链接失效反馈官方服务：
资源简介：
Supplementary materials for the article titled “Differences in Survival Improvement Between Known and Unknown Primary Merkel Cell Carcinoma in the Era of Immune Checkpoint Inhibitors”
Patient Consent: All data were de-identified and publicly available, thus the study was exempt from institutional review board approval and informed consent.
Finding: Overall, our findings suggest that ICIs may confer greater benefit in KPMCC than in UPMCC.
创建时间：
2025-10-01
